CPT 33410: Aortic Valve Replacement with Stentless Prosthesis
Medicare pays $2394 and commercial payers pay $3101 on average nationally for this procedure.
CPT code 33410 describes surgical replacement of the aortic valve with an artificial stentless valve to treat aortic valve stenosis or regurgitation; this is an open cardiac surgical procedure (aortic valve replacement) performed in an operating room or cardiac surgical suite and involves excision of the diseased valve and implantation of a stentless prosthetic to restore valve function and optimize blood flow.
For related coverage guidance, see recent payer policy updates: Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders, Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders, Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders.
Customize your policy alerts
Sign up for cpt 33410 policy alerts
Get alerted when payer policies referencing 33410 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
Medicare’s national mean rate of $2394 sits notably below BUCA’s average commercial mean of $3100.6, indicating that commercial BUCA contracts pay about $706.6 more on average for CPT 33410 than Medicare. The gap highlights a meaningful separation between Medicare reimbursement and one representative commercial aggregator; other commercial payers (e.g., Cigna, UnitedHealth Group) show even higher means, but the Medicare mean remains a central lower anchor at $2394.
Dispersion measured by the interquartile range (P75–P25) varies considerably across payers: Blue Cross Blue Shield has a range of $1,741.7, UnitedHealth Group $2,826.6, Cigna $2,735.5, Aetna $2,299.0, and BUCA $2,183.6. UnitedHealth Group displays the widest IQR, indicating the greatest middle-50% variability, while Blue Cross Blue Shield is the tightest among the named commercial payers. Medicare’s IQR is $190, reflecting relatively low middle-range variation compared with commercial payers.